James Ruhlmann, MD
Internal Medicine · Hutchinson, KSNPI 1316919426
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Novo Nordisk at 57.8% of the total.
Across 95 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$818
- AbbVie$141
- Pfizer$115
- Novartis$89
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$72
- Abbott$41
- plus $140 from 6 others
Across 1,466 payments — averaging $1890.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Emergent Biosolutions Inc.$1.2M
- Genentech, Inc.$649K
- Takeda Pharmaceuticals U.S.A., Inc.$362K
- Novartis$167K
- AstraZeneca$162K
- Regeneron$67K
- plus $207K from 7 others
What the payments were for
- Food & beverage$1,416100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $818 |
| AbbVie | 8 | $141 |
| Pfizer | 6 | $115 |
| Novartis | 6 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Abbott | 3 | $41 |
| Exact Sciences | 2 | $32 |
| Amgen | 2 | $30 |
| Insulet Corporation | 1 | $25 |
| Abiomed | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,416 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $174,630 |
| IngrezzaValbenazine Tosylate | 15 | $139,842 |
| TrulicityDulaglutide | 98 | $105,630 |
| OzempicSemaglutide | 86 | $101,668 |
| MounjaroTirzepatide | 69 | $81,875 |
| XareltoRivaroxaban | 53 | $58,866 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $49,021 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $45,029 |
| Bydureon BciseExenatide Microspheres | 48 | $44,689 |
| JanuviaSitagliptin Phosphate | 26 | $33,488 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $32,856 |
| Lamictal XrLamotrigine | 11 | $31,150 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $28,160 |
| JardianceEmpagliflozin | 22 | $25,937 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $25,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $115 | $182,033228 claims |
| Novo NordiskOzempic | $818 | $101,66886 claims |
| AbbVieLinzess | $141 | $24,02417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Hutchinson
- Mark YackleyHutchinson$10K
- Michael GreenHutchinson$7K
- Sara PatryHutchinson$5K
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.